Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors

ClinicalTrials.gov ID: NCT04900818

Public ClinicalTrials.gov record NCT04900818. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced May 7, 2026, 12:06 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1 Study of TJ033721 in Subjects With Advanced or Metastatic Solid Tumors

Study identification

NCT ID: NCT04900818
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 1
Lead sponsor: I-Mab Biopharma US Limited; Industry
Enrollment: 330 participants

Conditions and interventions

Conditions

Interventions

TJ033721 (givastomig) Drug
TJ033721 (givastomig) , nivolumab, chemotherapy Drug
TJ033721 (givastomig), chemotherapy Drug
TJ033721 (givastomig), durvalumab, chemotherapy Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jun 28, 2021
Primary completion: Nov 30, 2026
Completion: Nov 30, 2027
Last update posted: Mar 4, 2026

2021 – 2027

United States locations

U.S. sites: 11
U.S. states: 10
U.S. cities: 10

Facility	City	State	ZIP	Site status
Stern Center for Cancer Clinical Trials and Research	Orange	California	92868	Recruiting
UCHealth Cancer Care - Anschutz Medical Campus	Aurora	Colorado	80045	Recruiting
Horizon Oncology Research, LLC.	Layfayette	Indiana	47905	Completed
Mass General Hospital	Boston	Massachusetts	02114	Recruiting
Rutgers Cancer Institute of New Jersey	New Brunswick	New Jersey	08901	Completed
NYU Langone	New York	New York	10016	Recruiting
Memorial Sloan Kettering Cancer Center	New York	New York	10065	Recruiting
Carolina BioOncology Institute	Huntersville	North Carolina	28078	Completed
Vanderbilt-Ingram Cancer Center	Nashville	Tennessee	37232	Completed
Mary Crowley Cancer Research	Dallas	Texas	75230	Completed
UW Carbone Cancer Center	Madison	Wisconsin	53705	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 10 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT04900818, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Mar 4, 2026 · Synced May 7, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT04900818 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →